IRD Opus Genetics, Inc.
Company Analysis
Latest News
🔴 Opus Genetics is trading 5.7% down today as biotech sentiment weakens
Opus Genetics is trading 5.7% down at $5.49 on September 16, 2026, as biotech sentiment weakens in the absence of a new company-specific announcement. - The...
🟢 Opus Genetics is trading 6.3% up today after corrected OPGx-BEST1 data supported Phase 3
Opus Genetics is trading at $6.45, up +6.29% after correcting an immaterial visual-acuity calculation error in OPGx-BEST1 Cohort 1 data. - The revised...
Opus Genetics Corrects and Reissues Positive OPGx-BEST1 Phase 1/2 Clinical Data
Opus Genetics (IRD) filed a revised investor presentation to correct a self-described "immaterial error" in its previously announced clinical data for the...
🟢 Opus Genetics is trading 5.58% up today after positive low-dose BIRD-1 results
Opus Genetics is trading at $6.05, up 5.58% after positive low-dose Cohort 1 results from the Phase 1/2 BIRD-1 trial. - The stock is extending its September 9...
🟢 Opus Genetics is trading 7.33% up in after-hours trading after positive BIRD-1 Cohort 1 results
Opus Genetics is trading 7.33% up at $6.15 in after-hours trading after reporting positive low-dose Cohort 1 results from its Phase 1/2 BIRD-1 trial. • All...
Opus Genetics' Gene Therapy Trial Hits Every Mark — But Can a Five-Patient Study Justify a $566 Million Valuation?
Shares of Opus Genetics (Nasdaq: IRD) surged 57% to $6.81 in active morning trading after the company reported that all five patients in the first cohort of...
🟢 Opus Genetics is trading 60% up today after positive low-dose Cohort 1 BIRD-1 results
Opus Genetics is trading 59.91% up now at $6.81 after positive low-dose Cohort 1 results from its BIRD-1 Phase 1/2 trial. - All five participants showed...
🟢 Opus Genetics is trading 10.14% up in pre-market after all five low-dose participants reportedly improved vision
Opus Genetics is trading 10.14% up now at $4.78 after positive interim Phase 1/2 BIRD-1 data for OPGx-BEST1. - All five low-dose cohort participants...
🟢 Opus Genetics is trading 8.8% up in pre-market today after positive interim BIRD-1 data
Opus Genetics is trading 8.8% up in pre-market today at $4.72 after reporting positive interim Phase 1/2 BIRD-1 data for OPGx-BEST1. - All five participants...
Opus Genetics Reports Positive Phase 1/2 Data for OPGx-BEST1 Gene Therapy
Opus Genetics announced positive interim data from the low-dose cohort of its Phase 1/2 clinical trial (BIRD-1) for OPGx-BEST1, a gene therapy for inherited...
🔴 Opus Genetics is trading 5.05% down today ahead of September 9 OPGx-BEST1 Cohort 1 data
Opus Genetics is trading at $4.43, down 5.05%, after no clear negative company-specific announcement was identified for September 8, 2026. - Investors are...
BlackRock Buys $12.8 Million Opus Genetics Stake, Leading Institutional Investment
BlackRock Inc. acquired 3,116,487 shares of Opus Genetics for approximately $12.81 million. This investment establishes a 3.77% ownership stake in the company....
🟢 Opus Genetics is trading 6.7% up today ahead of September 9 Cohort 1 data webcast
Opus Genetics is trading at $4.75 (+6.72%) after its September 2 announcement of a September 9 webcast presenting topline Cohort 1 data from the Phase 1/2...
🟢 Opus Genetics is trading 6.1% up in pre-market ahead of September 9 topline data webcast
Opus Genetics is trading 6.1% up in pre-market at $4.72 after announcing a September 9 investor webcast for topline Cohort 1 data from its Phase 1/2 OPGx-BEST1...
Opus Genetics Surges on Bet That Gene Therapy Data Will Deliver — But Can a $4 Stock Survive a Binary Catalyst?
Shares of Opus Genetics (IRD) jumped 10.2% to $4.22 on September 2, extending a two-day rally of roughly 16.6% as traders pile into the micro-cap ahead of...
🟢 Opus Genetics is trading 10% up today ahead of expected OPGx-BEST1 Cohort 1 topline data
Opus Genetics is trading 10% up now at $4.22 on speculative positioning ahead of expected three-month topline data from the OPGx-BEST1 Cohort 1 study during...
🟢 Opus Genetics is trading 5% up today ahead of expected September 2026 topline data
Opus Genetics is trading 5% up now at $4.03, with the move appearing driven by speculative positioning ahead of three-month topline data from the OPGx-BEST1...
🟢 Opus Genetics is trading 5% up today amid speculative positioning ahead of unconfirmed September data
Opus Genetics is trading 5.11% up now at $3.81, with the move appearing consistent with speculative positioning ahead of anticipated three-month OPGx-BEST1...
🟢 Opus Genetics is trading 7.46% up in pre-market possibly reflecting positioning ahead of clinical data
Opus Genetics is trading 7.46% up at $3.89, with gains possibly reflecting speculative positioning ahead of clinical data, though no fresh company-specific...
🔴 Opus Genetics is trading 5% down today amid broader biotech weakness
Opus Genetics is trading 5.19% down now at $3.65, with the decline appearing primarily linked to broader biotech weakness; no company-specific catalyst was...